Schizophrenia Drug Candidate Met Trial Endpoints
Adults with acute schizophrenia saw improved symptom scores in a new clinical study of the drug alofropodect.
Updated on Sept. 29, 2026 in Mental Health
Live Poll
Do you trust that new clinical trial results for schizophrenia treatments represent significant medical progress?
A phase 2 clinical trial found that the experimental drug alofropodect helped reduce schizophrenia symptoms in hospitalized adults over four weeks. The study evaluated patients using the Positive and Negative Syndrome Scale (PANSS) to track clinical responses compared to a placebo.
Why it matters
This development represents a potential new treatment path for managing acute schizophrenia symptoms without the common metabolic side effects seen in existing antipsychotics. It follows years of research into PDE10A inhibition after previous attempts to target this enzyme in clinical settings had failed.
In a phase 2 trial of 189 hospitalized adults, the 40 mg dosage of alofropodect resulted in a -6.35 change in PANSS positive subscale scores. This study provides preliminary evidence of efficacy, though researchers continue to investigate optimal dosing and long-term outcomes.
The players
Celon Pharma
A pharmaceutical company based in Poland that focuses on research and development of innovative therapies for psychiatric and metabolic conditions.
University of Rhode Island
An academic institution with researchers who have historically contributed to the study of the PDE10A enzyme and its role in neurological health.
The details
Alofropodect acts as a phosphodiesterase 10A (PDE10A) inhibitor, which is hypothesized to modulate the indirect pathway of the basal ganglia. By targeting this specific enzyme, the drug aims to produce antipsychotic effects while avoiding common metabolic side effects like elevated blood glucose or cholesterol. During the trial, patients were given oral daily doses after a one-week medication washout period.
Timeline
1999: PDE10A enzyme expression in the striatum was identified.
2017-2019: Previous clinical trials of PDE10A inhibitors did not meet endpoints.
2021: Researchers published analysis on the lessons learned from earlier failed trials.
Week 4: Final primary PANSS endpoint assessment was completed.
Health Landscape
The development of alofropodect reflects a renewed effort to target the PDE10A enzyme following a period of stagnation in the field. This study updates the historical arc of schizophrenia research by successfully navigating trials that were informed by the analysis of earlier failures.
These findings are preliminary and do not indicate a change in current clinical care or medication management. Patients or caregivers interested in how these results may eventually impact treatment options should consult with a physician to discuss established therapies and clinical trial eligibility.
The takeaway
Alofropodect demonstrated clinical promise in reducing schizophrenia symptoms in an early-stage trial without the metabolic side effects seen in some current antipsychotics. Keep this area of research in view, and always consult a psychiatrist regarding any adjustments to personal treatment plans.
Further reading
For more on the current landscape of research and treatment, visit our Mental Health section.
Source note: This article includes information reported by Psychiatrictimes.
Live Poll
Do you trust that new clinical trial results for schizophrenia treatments represent significant medical progress?
